• Consensus Rating: Buy
  • Consensus Price Target: $310.17
  • Forecasted Upside: 14.11 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
▲ +3.58 (1.33%)

This chart shows the closing price for DHR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Danaher Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DHR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DHR

Analyst Price Target is $310.17
▲ +14.11% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Danaher in the last 3 months. The average price target is $310.17, with a high forecast of $340.00 and a low forecast of $265.00. The average price target represents a 14.11% upside from the last price of $271.82.

This chart shows the closing price for DHR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 contributing investment analysts is to buy stock in Danaher. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/29/2022BarclaysLower TargetOverweight$285.00 ➝ $277.00Low
10/27/2022Credit Suisse GroupLower Target$315.00Low
10/24/2022BenchmarkDowngradeBuy ➝ Hold$325.00Low
10/21/2022Robert W. BairdLower TargetOutperform$325.00 ➝ $315.00Low
10/21/2022JPMorgan Chase & Co.Lower TargetOverweight$350.00 ➝ $315.00Low
10/21/2022Royal Bank of CanadaLower TargetOutperform$318.00 ➝ $302.00Low
10/6/2022BarclaysLower TargetOverweight$310.00 ➝ $305.00Low
9/20/2022BenchmarkLower TargetBuy$345.00 ➝ $325.00Low
9/16/2022Royal Bank of CanadaBoost TargetOutperform$317.00 ➝ $318.00Low
8/24/2022Credit Suisse GroupInitiated CoverageOutperform$340.00Low
8/16/2022Sanford C. BernsteinInitiated CoverageOutperform$330.00 ➝ $340.00Low
7/28/2022UBS GroupBoost TargetBuy$297.00 ➝ $323.00Low
7/22/2022CowenLower Target$340.00Low
7/22/2022KeyCorpLower TargetOverweight$345.00 ➝ $325.00Low
7/22/2022Robert W. BairdBoost Target$319.00 ➝ $325.00Low
7/22/2022BarclaysBoost Target$290.00 ➝ $310.00Low
7/20/2022UBS GroupInitiated CoverageBuy$297.00Low
7/13/2022BarclaysLower TargetOverweight$320.00 ➝ $290.00N/A
7/5/2022Evercore ISILower TargetOutperform ➝ Outperform$320.00 ➝ $280.00N/A
6/1/2022Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$299.00 ➝ $310.00Medium
4/25/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$330.00 ➝ $265.00Low
4/24/2022UBS GroupLower Target$365.00 ➝ $340.00Medium
4/22/2022William BlairReiterated RatingOutperformHigh
4/22/2022Robert W. BairdLower TargetOutperform$334.00 ➝ $319.00High
4/22/2022Royal Bank of CanadaLower TargetSector Perform$311.00 ➝ $299.00High
1/28/2022Royal Bank of CanadaLower Target$344.00 ➝ $302.00High
1/28/2022Wells Fargo & CompanyLower TargetOverweight$350.00 ➝ $330.00High
1/28/2022Robert W. BairdLower Target$340.00 ➝ $334.00High
1/27/2022BarclaysLower TargetOverweight$355.00 ➝ $325.00Medium
1/10/2022Sanford C. BernsteinInitiated CoverageOutperform$365.00Low
12/14/2021Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$340.00 ➝ $350.00High
10/22/2021KeyCorpBoost TargetOverweight$315.00 ➝ $345.00Low
10/22/2021BarclaysBoost TargetOverweight$335.00 ➝ $355.00Low
10/22/2021Royal Bank of CanadaBoost TargetSector Perform$332.00 ➝ $334.00Low
10/22/2021Robert W. BairdBoost TargetOutperform$305.00 ➝ $340.00Low
10/22/2021CitigroupBoost TargetBuy$345.00 ➝ $370.00Low
9/10/2021Bank of AmericaBoost TargetBuy$340.00 ➝ $360.00Low
9/10/2021Credit Suisse GroupBoost TargetPositive ➝ Outperform$306.00 ➝ $370.00Low
9/8/2021Royal Bank of CanadaBoost TargetSector Perform$304.00 ➝ $332.00Low
7/23/2021The Goldman Sachs GroupBoost TargetBuy$280.00 ➝ $320.00Low
7/23/2021CowenBoost TargetPositive ➝ Outperform$275.00 ➝ $350.00Low
7/23/2021BarclaysBoost TargetOverweight$310.00 ➝ $335.00Low
7/23/2021Robert W. BairdBoost TargetOutperform$270.00 ➝ $305.00Low
7/23/2021Royal Bank of CanadaBoost TargetSector Perform$285.00 ➝ $304.00Low
7/16/2021BenchmarkInitiated CoverageBuy$330.00Medium
7/13/2021BarclaysBoost TargetOverweight$300.00 ➝ $310.00Low
6/18/2021Credit Suisse GroupBoost TargetOutperform$282.00 ➝ $288.00Low
4/26/2021William BlairReiterated RatingOutperformLow
4/26/2021BarclaysBoost TargetOverweight$265.00 ➝ $300.00Low
4/23/2021CitigroupBoost Target$275.00 ➝ $315.00Low
4/23/2021KeyCorpBoost TargetOverweight$280.00 ➝ $315.00High
4/23/2021Jefferies Financial GroupBoost TargetBuy$270.00 ➝ $290.00High
4/23/2021Robert W. BairdBoost TargetOutperform$249.00 ➝ $270.00High
4/23/2021Wells Fargo & CompanyBoost TargetOverweight$260.00 ➝ $280.00High
4/23/2021Royal Bank of CanadaBoost TargetSector Perform$253.00 ➝ $285.00High
3/8/2021BarclaysInitiated CoverageOverweight$260.00N/A
3/2/2021BarclaysInitiated CoverageOverweight$260.00Medium
1/14/2021Credit Suisse GroupBoost TargetOutperform$260.00 ➝ $264.00Low
12/2/2020The Goldman Sachs GroupInitiated CoverageBuy$250.00Low
11/25/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$273.00 ➝ $234.00Low
11/9/2020KeyCorpInitiated CoverageOverweight$280.00High
10/27/2020Needham & Company LLCBoost Target$209.00 ➝ $272.00Low
10/23/2020Royal Bank of CanadaBoost TargetOutperform$250.00 ➝ $273.00Medium
10/23/2020Robert W. BairdBoost TargetOutperform$205.00 ➝ $252.00Medium
9/29/2020Wells Fargo & CompanyReiterated RatingBuy$234.00Low
7/27/2020Needham & Company LLCBoost TargetBuy$183.00 ➝ $209.00Low
7/27/2020UBS GroupBoost TargetBuy$176.00 ➝ $233.00Low
7/24/2020Stifel NicolausBoost TargetHold$170.00 ➝ $210.00Low
7/24/2020Jefferies Financial GroupBoost TargetBuy$190.00 ➝ $230.00Low
7/24/2020Robert W. BairdBoost TargetOutperform$163.00 ➝ $205.00Medium
7/24/2020Royal Bank of CanadaBoost TargetOutperform$205.00 ➝ $218.00Medium
7/20/2020Bank of AmericaBoost TargetBuy$181.00 ➝ $215.00Low
7/20/2020Royal Bank of CanadaReiterated RatingBuy$205.00Low
6/16/2020Wolfe ResearchUpgradePeer Perform ➝ Outperform$195.00Low
5/21/2020Credit Suisse GroupBoost TargetOutperform$165.00 ➝ $169.00Low
5/15/2020Needham & Company LLCLower TargetBuy$187.00 ➝ $183.00High
5/11/2020Royal Bank of CanadaBoost TargetIn-Line ➝ Outperform$159.00 ➝ $173.00Low
5/8/2020Stifel NicolausBoost TargetHold$147.00 ➝ $170.00Low
5/8/2020CitigroupBoost TargetBuy$180.00 ➝ $190.00High
5/7/2020Bank of AmericaBoost TargetBuy$160.00 ➝ $181.00Medium
4/21/2020Wells Fargo & CompanyBoost TargetOverweight$155.00 ➝ $170.00Medium
4/20/2020CitigroupBoost TargetBuy$160.00 ➝ $180.00Low
4/2/2020Stifel NicolausLower TargetHold$162.00 ➝ $147.00Medium
4/2/2020Wolfe ResearchDowngradeOutperform ➝ Market Perform$154.00High
3/30/2020Wells Fargo & CompanyLower TargetOverweight$176.00 ➝ $155.00Medium
3/26/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector PerformLow
3/25/2020Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$151.00 ➝ $157.00High
3/23/2020Robert W. BairdReiterated RatingBuy$136.00High
3/20/2020CitigroupLower TargetBuy$195.00 ➝ $160.00Medium
2/3/2020CowenReiterated RatingBuy$170.00High
2/3/2020Needham & Company LLCBoost TargetBuy$167.00 ➝ $187.00Low
1/31/2020Bank of AmericaBoost TargetBuy$165.00 ➝ $188.00Low
1/31/2020Robert W. BairdBoost TargetOutperform$160.00 ➝ $175.00High
1/31/2020Stifel NicolausBoost TargetHold$150.00 ➝ $162.00High
1/31/2020CitigroupBoost TargetBuy$180.00 ➝ $195.00High
1/30/2020Piper SandlerBoost Target$142.00 ➝ $174.00High
1/10/2020UBS GroupBoost TargetNeutral$165.00 ➝ $176.00Low
1/7/2020Wells Fargo & CompanyInitiated CoverageOverweight$170.00Low
1/6/2020CitigroupInitiated CoverageBuy$180.00Low
1/2/2020Needham & Company LLCBoost TargetBuy$152.00 ➝ $167.00Low
12/19/2019JPMorgan Chase & Co.Boost Target$155.00 ➝ $175.00Medium
12/19/2019Credit Suisse GroupBoost TargetOutperform$151.00 ➝ $160.00Low
12/18/2019Royal Bank of CanadaReiterated RatingHold$145.00Medium
12/2/2019UBS GroupBoost TargetBuy$158.00 ➝ $165.00Low
11/14/2019Stifel NicolausReiterated RatingHold$150.00High
10/28/2019Needham & Company LLCLower TargetBuy$155.00 ➝ $152.00Low
10/25/2019Wolfe ResearchSet TargetBuy$154.00N/A
10/14/2019Credit Suisse GroupReiterated RatingOutperform$151.00Low
9/26/2019Wolfe ResearchSet TargetBuy$157.00Medium
7/23/2019ArgusBoost TargetBuy$165.00Low
7/19/2019Royal Bank of CanadaSet TargetHold$134.00Low
7/19/2019Robert W. BairdBoost TargetOutperform$131.00 ➝ $148.00Low
7/19/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$142.00 ➝ $155.00Low
7/18/2019Piper Jaffray CompaniesBoost TargetNeutral$148.00 ➝ $153.00Low
6/11/2019Piper Jaffray CompaniesInitiated CoverageNeutral ➝ Neutral$148.00Low
5/30/2019Wolfe ResearchInitiated CoverageOutperform ➝ OutperformMedium
4/17/2019Janney Montgomery ScottBoost TargetBuy$136.00 ➝ $174.00Medium
4/17/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$138.00 ➝ $141.00High
3/4/2019JPMorgan Chase & Co.Reiterated RatingOverweight$140.00Medium
2/28/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$114.00 ➝ $138.00Low
2/26/2019Jefferies Financial GroupBoost TargetBuy$140.00Medium
2/26/2019Deutsche Bank AktiengesellschaftBoost TargetBuy$130.00Medium
2/26/2019UBS GroupBoost TargetBuy$125.00 ➝ $144.00Medium
2/25/2019Janney Montgomery ScottUpgradeNeutral ➝ BuyHigh
1/7/2019CowenReiterated RatingBuy$110.00Low
1/2/2019Needham & Company LLCInitiated CoverageBuy ➝ Buy$114.00High
12/19/2018Royal Bank of CanadaReiterated RatingHold$102.00High
10/19/2018Robert W. BairdLower TargetOutperform ➝ Outperform$116.00 ➝ $114.00Medium
10/10/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$122.00 ➝ $126.00High
7/20/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$120.00 ➝ $122.00Medium
7/19/2018Royal Bank of CanadaBoost TargetSector Perform ➝ Positive$107.00Medium
7/19/2018Bank of AmericaSet TargetBuy$113.00Medium
7/13/2018Morgan StanleyBoost TargetOverweight$113.00 ➝ $120.00Low
4/20/2018BarclaysReiterated RatingBuy$113.00Low
4/20/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$112.00 ➝ $113.00Low
4/20/2018Jefferies Financial GroupReiterated RatingBuy$117.00Low
4/20/2018Robert W. BairdReiterated RatingBuy$106.00Low
4/19/2018Stifel NicolausReiterated RatingBuy ➝ Buy$108.00 ➝ $114.00Low
4/10/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$110.00 ➝ $112.00Low
3/13/2018Credit Suisse GroupBoost TargetOutperform ➝ Outperform$106.00 ➝ $108.00Low
3/9/2018Credit Suisse GroupReiterated RatingHold ➝ OutperformLow
3/1/2018Deutsche Bank AktiengesellschaftLower TargetBuy ➝ Buy$114.00 ➝ $107.00Low
2/15/2018BarclaysInitiated CoverageOverweight ➝ Overweight$110.00Low
2/1/2018ArgusBoost TargetBuy$100.00 ➝ $115.00Low
1/31/2018Royal Bank of CanadaReiterated RatingHold$98.00Low
1/31/2018Stifel NicolausBoost TargetBuy ➝ Buy$110.00 ➝ $115.00Low
1/31/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$103.00 ➝ $110.00Low
1/31/2018Credit Suisse GroupBoost TargetOutperform ➝ Outperform$99.00 ➝ $105.00Low
1/30/2018CowenReiterated RatingBuy$110.00Low
1/22/2018UBS GroupInitiated CoverageBuy$116.00 ➝ $99.97Low
1/19/2018Stifel NicolausReiterated RatingBuy$110.00Low
1/12/2018Robert W. BairdReiterated RatingBuyLow
1/4/2018Royal Bank of CanadaReiterated RatingHold$96.00Low
1/3/2018Evercore ISIInitiated CoverageOutperformLow
12/19/2017Credit Suisse GroupReiterated RatingHold$99.00Low
12/15/2017Robert W. BairdReiterated RatingBuy$99.00Low
12/15/2017CitigroupBoost TargetBuy$107.00High
(Data available from 12/8/2017 forward)

News Sentiment Rating

0.67 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 11 very positive mentions
  • 53 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 7 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 8 very positive mentions
  • 53 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
  • 3 very positive mentions
  • 37 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
  • 7 very positive mentions
  • 47 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
  • 11 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 11 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Danaher logo
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
Read More

Today's Range

Now: $271.82
Low: $266.42
High: $273.47

50 Day Range

MA: $260.26
Low: $241.42
High: $282.29

52 Week Range

Now: $271.82
Low: $233.71
High: $331.23


1,631,663 shs

Average Volume

2,672,858 shs

Market Capitalization

$197.87 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Danaher?

The following equities research analysts have issued reports on Danaher in the last twelve months: Barclays PLC, Benchmark Co., Cowen Inc., Credit Suisse Group AG, Evercore ISI, JPMorgan Chase & Co., KeyCorp, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, StockNews.com, UBS Group AG, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for DHR.

What is the current price target for Danaher?

12 Wall Street analysts have set twelve-month price targets for Danaher in the last year. Their average twelve-month price target is $310.17, suggesting a possible upside of 14.1%. Sanford C. Bernstein has the highest price target set, predicting DHR will reach $340.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $265.00 for Danaher in the next year.
View the latest price targets for DHR.

What is the current consensus analyst rating for Danaher?

Danaher currently has 2 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DHR will outperform the market and that investors should add to their positions of Danaher.
View the latest ratings for DHR.

What other companies compete with Danaher?

How do I contact Danaher's investor relations team?

Danaher's physical mailing address is 2200 PENNSYLVANIA AVE. N.W SUITE 800W, WASHINGTON DC, 20037. The conglomerate's listed phone number is (202) 828-0850 and its investor relations email address is [email protected] The official website for Danaher is www.danaher.com. Learn More about contacing Danaher investor relations.